Cormorant Asset Management, LP Protagonist Therapeutics, Inc Transaction History

Cormorant Asset Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$18.02 - $29.36 $3.6 Million - $5.87 Million	-200,000 Reduced 11.76%	1,500,000 $41.4 Million
Q1 2023 May 15, 2023	BUY	$10.78 - $25.38 $18.3 Million - $43.1 Million	1,700,000 New	1,700,000 $39.1 Million
Q3 2018 Nov 14, 2018	SELL	$6.82 - $11.26 $2.61 Million - $4.3 Million	-382,139 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$8.46 - $23.08 $151,104 - $412,231	-17,861 Reduced 4.47%	382,139 $3.28 Million
Q4 2017 Feb 14, 2018	SELL	$14.47 - $20.8 $1.45 Million - $2.08 Million	-100,000 Reduced 20.0%	400,000 $8.32 Million
Q3 2017 Nov 14, 2017	BUY	$10.61 - $17.98 $5.31 Million - $8.99 Million	500,000	500,000 $8.84 Million

247

56.4M

76.3K

114K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.92B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.